Cargando…
Design of Infusion Schemes for Neuroreceptor Imaging: Application to [(11)C]Flumazenil-PET Steady-State Study
This study aims at developing a simulation system that predicts the optimal study design for attaining tracer steady-state conditions in brain and blood rapidly. Tracer kinetics was determined from bolus studies and used to construct the system. Subsequently, the system was used to design inputs for...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830710/ https://www.ncbi.nlm.nih.gov/pubmed/27123457 http://dx.doi.org/10.1155/2016/9132840 |
_version_ | 1782426933994192896 |
---|---|
author | Feng, Ling Svarer, Claus Madsen, Karine Ziebell, Morten Dyssegaard, Agnete Ettrup, Anders Hansen, Hanne Demant Lehel, Szabolcs Yndgaard, Stig Paulson, Olaf Bjarne Knudsen, Gitte Moos Pinborg, Lars Hageman |
author_facet | Feng, Ling Svarer, Claus Madsen, Karine Ziebell, Morten Dyssegaard, Agnete Ettrup, Anders Hansen, Hanne Demant Lehel, Szabolcs Yndgaard, Stig Paulson, Olaf Bjarne Knudsen, Gitte Moos Pinborg, Lars Hageman |
author_sort | Feng, Ling |
collection | PubMed |
description | This study aims at developing a simulation system that predicts the optimal study design for attaining tracer steady-state conditions in brain and blood rapidly. Tracer kinetics was determined from bolus studies and used to construct the system. Subsequently, the system was used to design inputs for bolus infusion (BI) or programmed infusion (PI) experiments. Steady-state quantitative measurements can be made with one short scan and venous blood samples. The GABA(A) receptor ligand [(11)C]Flumazenil (FMZ) was chosen for this purpose, as it lacks a suitable reference region. Methods. Five bolus [(11)C]FMZ-PET scans were conducted, based on which population-based PI and BI schemes were designed and tested in five additional healthy subjects. The design of a PI was assisted by an offline feedback controller. Results. The system could reproduce the measurements in blood and brain. With PI, [(11)C]FMZ steady state was attained within 40 min, which was 8 min earlier than the optimal BI (B/I ratio = 55 min). Conclusions. The system can design both BI and PI schemes to attain steady state rapidly. For example, subjects can be [(11)C]FMZ-PET scanned after 40 min of tracer infusion for 40 min with venous sampling and a straight-forward quantification. This simulation toolbox is available for other PET-tracers. |
format | Online Article Text |
id | pubmed-4830710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-48307102016-04-27 Design of Infusion Schemes for Neuroreceptor Imaging: Application to [(11)C]Flumazenil-PET Steady-State Study Feng, Ling Svarer, Claus Madsen, Karine Ziebell, Morten Dyssegaard, Agnete Ettrup, Anders Hansen, Hanne Demant Lehel, Szabolcs Yndgaard, Stig Paulson, Olaf Bjarne Knudsen, Gitte Moos Pinborg, Lars Hageman Biomed Res Int Research Article This study aims at developing a simulation system that predicts the optimal study design for attaining tracer steady-state conditions in brain and blood rapidly. Tracer kinetics was determined from bolus studies and used to construct the system. Subsequently, the system was used to design inputs for bolus infusion (BI) or programmed infusion (PI) experiments. Steady-state quantitative measurements can be made with one short scan and venous blood samples. The GABA(A) receptor ligand [(11)C]Flumazenil (FMZ) was chosen for this purpose, as it lacks a suitable reference region. Methods. Five bolus [(11)C]FMZ-PET scans were conducted, based on which population-based PI and BI schemes were designed and tested in five additional healthy subjects. The design of a PI was assisted by an offline feedback controller. Results. The system could reproduce the measurements in blood and brain. With PI, [(11)C]FMZ steady state was attained within 40 min, which was 8 min earlier than the optimal BI (B/I ratio = 55 min). Conclusions. The system can design both BI and PI schemes to attain steady state rapidly. For example, subjects can be [(11)C]FMZ-PET scanned after 40 min of tracer infusion for 40 min with venous sampling and a straight-forward quantification. This simulation toolbox is available for other PET-tracers. Hindawi Publishing Corporation 2016 2016-03-31 /pmc/articles/PMC4830710/ /pubmed/27123457 http://dx.doi.org/10.1155/2016/9132840 Text en Copyright © 2016 Ling Feng et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Feng, Ling Svarer, Claus Madsen, Karine Ziebell, Morten Dyssegaard, Agnete Ettrup, Anders Hansen, Hanne Demant Lehel, Szabolcs Yndgaard, Stig Paulson, Olaf Bjarne Knudsen, Gitte Moos Pinborg, Lars Hageman Design of Infusion Schemes for Neuroreceptor Imaging: Application to [(11)C]Flumazenil-PET Steady-State Study |
title | Design of Infusion Schemes for Neuroreceptor Imaging: Application to [(11)C]Flumazenil-PET Steady-State Study |
title_full | Design of Infusion Schemes for Neuroreceptor Imaging: Application to [(11)C]Flumazenil-PET Steady-State Study |
title_fullStr | Design of Infusion Schemes for Neuroreceptor Imaging: Application to [(11)C]Flumazenil-PET Steady-State Study |
title_full_unstemmed | Design of Infusion Schemes for Neuroreceptor Imaging: Application to [(11)C]Flumazenil-PET Steady-State Study |
title_short | Design of Infusion Schemes for Neuroreceptor Imaging: Application to [(11)C]Flumazenil-PET Steady-State Study |
title_sort | design of infusion schemes for neuroreceptor imaging: application to [(11)c]flumazenil-pet steady-state study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830710/ https://www.ncbi.nlm.nih.gov/pubmed/27123457 http://dx.doi.org/10.1155/2016/9132840 |
work_keys_str_mv | AT fengling designofinfusionschemesforneuroreceptorimagingapplicationto11cflumazenilpetsteadystatestudy AT svarerclaus designofinfusionschemesforneuroreceptorimagingapplicationto11cflumazenilpetsteadystatestudy AT madsenkarine designofinfusionschemesforneuroreceptorimagingapplicationto11cflumazenilpetsteadystatestudy AT ziebellmorten designofinfusionschemesforneuroreceptorimagingapplicationto11cflumazenilpetsteadystatestudy AT dyssegaardagnete designofinfusionschemesforneuroreceptorimagingapplicationto11cflumazenilpetsteadystatestudy AT ettrupanders designofinfusionschemesforneuroreceptorimagingapplicationto11cflumazenilpetsteadystatestudy AT hansenhannedemant designofinfusionschemesforneuroreceptorimagingapplicationto11cflumazenilpetsteadystatestudy AT lehelszabolcs designofinfusionschemesforneuroreceptorimagingapplicationto11cflumazenilpetsteadystatestudy AT yndgaardstig designofinfusionschemesforneuroreceptorimagingapplicationto11cflumazenilpetsteadystatestudy AT paulsonolafbjarne designofinfusionschemesforneuroreceptorimagingapplicationto11cflumazenilpetsteadystatestudy AT knudsengittemoos designofinfusionschemesforneuroreceptorimagingapplicationto11cflumazenilpetsteadystatestudy AT pinborglarshageman designofinfusionschemesforneuroreceptorimagingapplicationto11cflumazenilpetsteadystatestudy |